Pharmacokinetic interaction between metoprolol and SP-8203 in rats: Competitive inhibition for the metabolism of metoprolol by SP-8203 via hepatic CYP2D subfamily

Xenobiotica

Volumn 42, Issue 10, 2012, Pages 1017-1027

  Han, Seung Yon ^a   Yoon, Insoo ^b   Chin, Young Won ^a   Cho, Il Whan ^b   Lee, Myung Gull ^c   Choi, Young Hee ^a  

^a Dongguk University   (South Korea)

^b Seoul National University   (South Korea)

^c Shinpoong Pharmaceutical Co   (South Korea)

Author keywords

CYP2D; Hepatic metabolism; Inhibition; Metoprolol; Pharmacokinetics; SP 8203

Indexed keywords

CYTOCHROME P450 2D; CYTOCHROME P450 3A; INDOCYANINE GREEN; METOPROLOL TARTRATE; NEUROPROTECTIVE AGENT; SP 8203; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACULOVIRUS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; EQUILIBRIUM DIALYSIS; FLOW RATE; INSECT CELL; LIVER BLOOD FLOW; MALE; MICROSOME; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; VIRUS INFECTION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BACULOVIRIDAE; CYTOCHROME P-450 ENZYME SYSTEM; DIALYSIS; DRUG INTERACTIONS; HUMANS; INTESTINES; KINETICS; LIVER; MALE; METOPROLOL; MICROSOMES, LIVER; QUINAZOLINONES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; TIME FACTORS;

RATTUS;

EID: 84865851075     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.663117     Document Type: Article

References (40)

1. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association/American Stroke Association Stroke Council; American Heart Association/American Stroke Association Clinical Cardiology Council; American Heart Association/American Stroke Association Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease Working Group; Quality of Care Outcomes in Research Interdisciplinary Working Group. (2007). Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115:e478-e534.
2. Badgett RG, Lawrence VA, Cohn SL. (2010). Variations in pharmacology of β-blockers may contribute to heterogeneous results in trials of perioperative β-blockade. Anesthesiology 113:585-592.
3. Baraka MM. (2001). Synthesis of novel 2,4 (1H, 3H)-quinazolinedione derivatives with analgesic and anti-inflammatory activities. Boll Chim Farm 140:90-96.
4. Bachmann KA, Lewis JD. (2005). Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
5. Bianchi S, Bigazzi R, Amoroso A, Campese VM. (2003). Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. J Hum Hypertens 17:13-20.
6. Boralli VB, Coelho EB, Lanchote VL. (2009). Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats. Chirality 21:886-893.
7. Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
8. Choi YH, Lee MG. (2006). Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: Involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol 149:424-430.
9. Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-2552.
10. Choi YH, Chung SJ, Lee MG. (2008). Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: Competitive inhibition of metabolism via hepatic CYP3A1/2. Br J Pharmacol 153:1568-1578.
11. Conney AH. (1971). Environmental factors influencing drug metabolism. In: La Du BN, Mandel HG, Way EL, (eds). Fundamentals of drug metabolism and drug disposition. Williams & Wilkins Company, Baltimore: p. 269.
12. Collett A, Tanianis-Hughes J, Warhurst G. (2004). Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: A possible source of transporter mediated drug interactions? Biochem Pharmacol 68:783-790.
13. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61-90.
14. Dziedzic T, Slowik A, Pera J, Szczudlik A. (2007). β-blockers reduce the risk of early death in ischemic stroke. J Neurol Sci 252:53-56.
15. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA. (2000). Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44:313-324.
16. Fleck C, Bräunlich H. (1986). Relation between renal and hepatic excretion of drugs. II. Age-dependence of phenol red excretion in comparison with those of p-aminohippurate and indocyanine green. Exp Pathol 29:235-247.
17. Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd Edn. New York: Marcel Dekker.
18. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. (2001). Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 32:280-299.
19. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. (2008). Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-396.
20. He J, Whelton PK. (1997). Epidemiology and prevention of hypertension. Med Clin North Am 81:1077-1097.
21. Hemeryck A, De Vriendt CA, Belpaire FM. (2001). Metoprololparoxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction. Drug Metab Dispos 29:656-663.
22. Joo EH, Lee YB. (1998). No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. Arch Pharm Res 21:411-417.
23. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. (2005). Global burden of hypertension: Analysis of worldwide data. Lancet 365:217-223.
24. Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
25. Lee KJ, Kim JR, Lee CH. (2005). Effect of 2-methylaminoethyl- 4,4′-dimethoxy-5,6,5′, 6′-dimethylenedioxybiphenyl-2- carboxylic acid-2′-carboxylate monohydrochloride (DDB-S) on indocyanine green (ICG) clearance in rats. Arch Pharm Res 28: 115-119.
26. Lee JH, Choi YH, Suh JH, Kang HE, Lee TH, Cho IH, Lee MG. (2010). Dose-dependent pharmacokinetics of SP-8203 in rats. Biopharm Drug Dispos 31:358-361.
27. Lewis DFV. (1996). P450 specificity and metabolism. In: Lewis DFV, (eds).: Taylor & Francis Bristol, p. 123.
28. Lineweaver H, Burk D. (1934). The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
29. Neuhoff S, Ungell AL, Zamora I, Artursson P. (2003). pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharm Res 20:1141-1148.
30. Noh SJ, Lee SH, Shin KY, Lee CK, Cho IH, Kim HS, Suh YH. (2011). SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav 98:150-154.
31. Noji T, Nan-ya K, Mizutani M, Katagiri C, Sano J, Takada C, Nishikawa S, Karasawa A, Kusaka H. (2002). KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice. Eur J Pharmacol 454:85-93.
32. Segel I. (1975). Enzyme kinetics. behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: Wiley, pp. 100-206.
33. Soucek P, Gut I. (1992). Cytochromes P-450 in rats: Structures, functions, properties and relevant human forms. Xenobiotica 22:83-103.
34. Strandgaard S, Paulson OB. (1989). Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 2: 486-492.
35. Tanabe H, Taira S, Taguchi M, Hashimoto Y. (2007). Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull 30:552-555.
36. Whelton PK. (1994). Epidemiology of hypertension. Lancet 344:101-106.
37. Wilkinson GR, Shand DG. (1975). Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
38. Yang KH, Lee JH, Lee MG. (2008). Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: Involvement of CYP1A1/2 in the formation of 1,3-DMU. J Pharm Pharmacol 60:45-53.
39. Yoon IS, Choi MK, Kim JS, Shim CK, Chung SJ, Kim DD. (2011). Pharmacokinetics and first-pass elimination of metoprolol in rats: Contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243-251.
40. Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198.